Bicara Therapeutics (BCAX) Liabilities and Shareholders Equity (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Liabilities and Shareholders Equity of $553.6 million for Q1 2026, up 15.8% year-over-year from $478.1 million in Q1 2025, and up 28.45% quarter-over-quarter from $431.0 million in Q4 2025.
Bicara Therapeutics (BCAX) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $553.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 15.8% year-over-year to $553.6 million; the TTM figure through Mar 2026 stood at $1.9 billion (up 23.19% YoY), while the FY2025 annual figure was $431.0 million, down 15.49% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $553.6 million, up from $431.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $553.6 million in Q1 2026, with the low at $234.0 million in Q4 2023.
- The 4-year median for Liabilities and Shareholders Equity is $465.8 million (2025), against an average of $451.1 million.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 117.96% in 2024, then dropped 18.98% in 2025.
- Bicara Therapeutics' Liabilities and Shareholders Equity stood at $234.0 million in 2023, then surged by 117.96% to $510.0 million in 2024, then dropped by 15.49% to $431.0 million in 2025, then grew by 28.45% to $553.6 million in 2026.
- Business Quant data shows BCAX's Liabilities and Shareholders Equity at $553.6 million in Q1 2026, $431.0 million in Q4 2025, and $424.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 512.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 512.24 Mn |
| Mar 31, 2026 | 553.60 Mn |
| Dec 31, 2025 | 430.99 Mn |
| Sep 30, 2025 | 424.69 Mn |
| Jun 30, 2025 | 453.59 Mn |
| Mar 31, 2025 | 478.08 Mn |
| Dec 31, 2024 | 510.00 Mn |
| Sep 30, 2024 | 524.17 Mn |
| Dec 31, 2023 | 233.98 Mn |